Dimitrios P Kontoyiannis

List of Publications by Citations

185 papers	16,395 citations	62 h-index	126 g-index
198 ext. papers	19,380 ext. citations	7.7 avg, IF	6.75 L-index

#	Paper	IF	Citations
185	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2016**, 63, e1-e60	11.6	1274
184	Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clinical Infectious Diseases*, **2010**, 50, 1101-11	11.6	1048
183	Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clinical Infectious Diseases*, **2010**, 50, 1091-100	11.6	991
182	Epidemiology and clinical manifestations of mucormycosis. *Clinical Infectious Diseases*, **2012**, 54 Suppl 1, S23-34	11.6	760
181	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
180	Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. *Journal of Infectious Diseases*, **2005**, 191, 1350-60	7	583
179	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet, The*, **2016**, 387, 760-9	40	501
178	Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clinical Infectious Diseases*, **2006**, 42, e61-5	11.6	490
177	Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. *Clinical Infectious Diseases*, **2008**, 47, 503-9	11.6	489
176	Glucocorticoids and invasive fungal infections. *Lancet, The*, **2003**, 362, 1828-38	40	426
175	Zygomycosis in the 1990s in a tertiary-care cancer center. *Clinical Infectious Diseases*, **2000**, 30, 851-6	11.6	411
174	Pathogenesis of mucormycosis. *Clinical Infectious Diseases*, **2012**, 54 Suppl 1, S16-22	11.6	362
173	Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). *Haematologica*, **2006**, 91, 986-9	6.6	333
172	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clinical Infectious Diseases*, **2008**, 47, 674-83	11.6	308
171	T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clinical Infectious Diseases*, **2015**, 60, 892-9	11.6	305
170	Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Annals of Internal Medicine*, **2015**, 162, 81-9	8	286
169	Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. *Clinical Infectious Diseases*, **2004**, 39, 192-8	11.6	253

168	Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. *Journal of Clinical Microbiology*, **2009**, 47, 3138-41	9.7	214
167	Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. *Emerging Infectious Diseases*, **2011**, 17, 1855-64	10.2	209
166	The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 715-22	5.1	201
165	Diagnosis of Invasive Septate Mold Infections. *American Journal of Clinical Pathology*, **2003**, 119, 854-858	1.9	180
164	Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. *Clinical Infectious Diseases*, **2018**, 66, 140-148	11.6	165
163	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. *Mycoses*, **2013**, 56, 638-45	5.2	160
162	Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. *Journal of Infectious Diseases*, **2008**, 198, 186-92	7	156
161	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10660-5	11.5	130
160	Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. *Cell Host and Microbe*, **2016**, 19, 79-90	23.4	127
159	On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds. *MBio*, **2019**, 10,	7.8	125
158	Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. *Journal of Infection*, **2010**, 60, 331-7	18.9	118
157	Drug-resistant Candida glabrata infection in cancer patients. *Emerging Infectious Diseases*, **2014**, 20, 1833-40	11.2	116
156	Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. *Journal of Infectious Diseases*, **1995**, 172, 599-602	7	116
155	Mold infections of the central nervous system. *New England Journal of Medicine*, **2014**, 371, 150-60	59.2	114
154	Combination therapy for mucormycosis: why, what, and how?. *Clinical Infectious Diseases*, **2012**, 54 Suppl 1, S73-8	11.6	111
153	Mucormycoses. *Infectious Disease Clinics of North America*, **2016**, 30, 143-63	6.5	110
152	Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2518-23	5.9	110
151	Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. *Cancer*, **2004**, 101, 1594-600	6.4	109

150	Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. *Journal of Infectious Diseases*, **2011**, 204, 626-35	7	106
149	Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 9367-72	11.5	106
148	Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. *Journal of Infection*, **2012**, 64, 68-75	18.9	104
147	Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. *Journal of Infectious Diseases*, **2009**, 199, 1399-406	7	104
146	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. *Journal of Infectious Diseases*, **2017**, 216, S474-S483	7	103
145	Guidelines and recommendations on yeast cell death nomenclature. *Microbial Cell*, **2018**, 5, 4-31	3.9	96
144	Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. *Cancer*, **2004**, 101, 2859-65	6.4	91
143	Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. *Journal of Clinical Microbiology*, **2005**, 43, 6120-2	9.7	88
142	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer*, **2016**, 122, 2186-96	6.4	85
141	Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. *PLoS ONE*, **2010**, 5, e12955	3.7	83
140	Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6993-5	5.9	82
139	Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. *Blood*, **2009**, 114, 5393-9	2.2	81
138	359. Baseline Serum Aspergillus Galactomannan Index Among Aspergillus Species in Hematologic Malignancies Patients With Invasive Pulmonary Aspergillosis. *Open Forum Infectious Diseases*, **2018**, 5, S141-S141	1	78
137	Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. *Clinical Infectious Diseases*, **2006**, 42, 1584-91	11.6	77
136	Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. *Mycoses* , **2019**, 62, 716-729	5.2	76
135	Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. *Diagnostic Microbiology and Infectious Disease*, **2005**, 52, 15-20	2.9	75
134	Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. *American Journal of Clinical Pathology*, **2003**, 119, 854-8	1.9	75
133	Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. *Journal of Infectious Diseases*, **2005**, 191, 1188-95	7	73

132	Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA. *Emerging Infectious Diseases*, **2015**, 21, 1942-50	10.2	70
131	Toward more effective antifungal therapy: the prospects of combination therapy. *British Journal of Haematology*, **2004**, 126, 165-75	4.5	69
130	Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. *Cancer*, **2006**, 106, 2664-71	6.4	68
129	Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. *BMC Infectious Diseases*, **2016**, 16, 730	4	68
128	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). *Medical Mycology*, **2015**, 53, 440-6	3.9	65
127	Epidemiology and treatment of mucormycosis. *Future Microbiology*, **2013**, 8, 1163-75	2.9	64
126	Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. *Pharmacotherapy*, **2007**, 27, 1644-50	5.8	63
125	Advances in the diagnosis and treatment of fungal infections of the CNS. *Lancet Neurology, The*, **2018**, 17, 362-372	24.1	62
124	Invasive mycoses: strategies for effective management. *American Journal of Medicine*, **2012**, 125, S25-38	2.4	62
123	Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. *Clinical Infectious Diseases*, **2018**, 67, 1621-1630	11.6	59
122	Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *Journal of Clinical Investigation*, **2016**, 126, 2280-94	15.9	57
121	The Candida auris Alert: Facts and Perspectives. *Journal of Infectious Diseases*, **2018**, 217, 516-520	7	54
120	Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. *Clinical Infectious Diseases*, **2018**, 67, 1610-1613	11.6	54
119	Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. *Cancer*, **2011**, 117, 3424-33	6.4	53
118	The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. *Medical Mycology*, **2008**, 46, 23-9	3.9	52
117	Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	51
116	Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. *Genome Medicine*, **2017**, 9, 21	14.4	51
115	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus. *PeerJ*, **2013**, 1, e4	3.1	50

114	Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2798-800	5.9	49
113	Azole-Resistance in and Related Species: An Emerging Problem or a Rare Phenomenon?. *Frontiers in Microbiology*, **2018**, 9, 516	5.7	46
112	Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 484-90	5.9	44
111	Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. *Journal of Clinical Microbiology*, **2007**, 45, 2686-90	9.7	44
110	Antifungal agents and liver toxicity: a complex interaction. *Expert Review of Anti-Infective Therapy*, **2016**, 14, 765-76	5.5	43
109	Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. *Journal of Infectious Diseases*, **2013**, 207, 834-41	7	43
108	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. *PLoS ONE*, **2015**, 10, e0139851	3.7	42
107	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. *Clinical Infectious Diseases*, **2017**, 65, 216-225	11.6	39
106	Increased culture recovery of Zygomycetes under physiologic temperature conditions. *American Journal of Clinical Pathology*, **2007**, 127, 208-12	1.9	39
105	Therapeutic Challenges of Non- Invasive Mold Infections in Immunosuppressed Patients. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	38
104	Methods of Controlling Invasive Fungal Infections Using CD8 T Cells. *Frontiers in Immunology*, **2017**, 8, 1939	8.4	38
103	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. *Blood*, **2015**, 126, 2790-7	2.2	37
102	Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6767-72	5.9	37
101	Recent advances in the molecular diagnosis of mucormycosis. *Expert Review of Molecular Diagnostics*, **2018**, 18, 845-854	3.8	37
100	Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. *Journal of Clinical Microbiology*, **2005**, 43, 382-6	9.7	36
99	Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. *PLoS ONE*, **2016**, 11, e0150155	3.7	36
98	Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence. *Virulence*, **2012**, 3, 95-7	4.7	35
97	Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. *Clinical Infectious Diseases*, **2020**, 71, 63-71	11.6	34

96	Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. *Pharmacotherapy*, **2005**, 25, 1174-80	5.8	32
95	Antifungal Resistance: An Emerging Reality and A Global Challenge. *Journal of Infectious Diseases*, **2017**, 216, S431-S435	7	31
94	Isavuconazole: a new extended spectrum triazole for invasive mold diseases. *Future Microbiology*, **2015**, 10, 693-708	2.9	31
93	The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer. *Cancer*, **2004**, 100, 165-72	6.4	30
92	Invasive fungal disease and cytomegalovirus infection: is there an association?. *Current Opinion in Infectious Diseases*, **2018**, 31, 481-489	5.4	27
91	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 757-763	5.1	26
90	Fungal infections in transplant and oncology patients. *Hematology/Oncology Clinics of North America*, **2011**, 25, 193-213	3.1	24
89	Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. *Medical Mycology*, **2010**, 48, 310-317	3.9	24
88	Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. *Virulence*, **2011**, 2, 280-95	4.7	24
87	Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?. *Journal of Infection*, **2012**, 65, 262-8	18.9	23
86	The impact of azole resistance on aspergillosis guidelines. *Annals of the New York Academy of Sciences*, **2012**, 1272, 15-22	6.5	22
85	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. *Clinical Infectious Diseases*, **2021**, 72, 1755-1763	11.6	22
84	Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. *Journal of Fungi (Basel, Switzerland)*, **2019**, 5,	5.6	21
83	Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1904-1910	5.1	21
82	Pentamidine is active in vitro against Fusarium species. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 3252-9	5.9	21
81	Checkpoint Inhibition and Infectious Diseases: A Good Thing?. *Trends in Molecular Medicine*, **2019**, 25, 1080-1093	11.5	20
80	Recent Advances in the Use of Drosophila melanogaster as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. *International Journal of Microbiology*, **2012**, 2012, 583792	3.6	20
79	The Cephalosporin eraSof triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1543-58	4	19

78	Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the infectious diseases society of america. *Clinical Infectious Diseases*, **2009**, 49, 638-9; author reply 639-40	11.6	19
77	Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. *Mycoses*, **2019**, 62, 81-86	5.2	19
76	Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. *Journal of Infection*, **2017**, 75, 572-580	18.9	18
75	A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case. *Mycopathologia*, **2014**, 178, 465-70	2.9	18
74	Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. *Journal of Infectious Diseases*, **2013**, 207, 1066-74	7	18
73	Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae. *Journal of Infectious Diseases*, **2016**, 214, 114-21	7	17
72	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. *Journal of Fungi (Basel, Switzerland)*, **2020**, 7,	5.6	17
71	Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. *ACS Biomaterials Science and Engineering*, **2017**, 3, 1207-1220	5.5	16
70	Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. *Mycoses*, **2018**, 61, 245-255	5.2	16
69	Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. *Open Forum Infectious Diseases*, **2019**, 6, ofz247	1	16
68	Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. *Medical Mycology*, **2012**, 50, 543-8	3.9	16
67	Environmental Candida auris and the Global Warming Emergence Hypothesis. *MBio*, **2021**, 12,	7.8	16
66	Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017. *Morbidity and Mortality Weekly Report*, **2019**, 68, 469-473	31.7	15
65	Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. *Medical Mycology*, **2010**, 48, 310-7	3.9	15
64	Breath-Based Diagnosis of Invasive Mucormycosis (IM). *Open Forum Infectious Diseases*, **2017**, 4, S53-S54	1	14
63	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. *Journal of Infection*, **2019**, 78, 484-490	18.9	13
62	Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. *Clinical Infectious Diseases*, **2001**, 32, E94-6	11.6	13
61	Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. *Clinical Infectious Diseases*, **2014**, 59 Suppl 5, S356-9	11.6	12

60	Effect of fluconazole on agar invasion by Candida albicans. *Journal of Medical Microbiology*, **2001**, 50, 78-82	3.2	12
59	Rhodotorula infection in haematological patient: Risk factors and outcome. *Mycoses*, **2019**, 62, 223-229	5.2	12
58	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. *Cancer*, **2021**, 127, 2489-2499	6.4	11
57	Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. *MBio*, **2019**, 10,	7.8	10
56	Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model. *Journal of Infectious Diseases*, **2020**, 222, 989-994	7	10
55	How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. *Clinical Infectious Diseases*, **2020**, 71, 685-692	11.6	10
54	Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 229-36	5.9	10
53	Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy. *Clinical Infectious Diseases*, **2019**, 69, 1624-1627	11.6	9
52	Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3100-6	5.1	9
51	How to prophylax against invasive fungal infections in adult ALL? An unmet need. *Mycoses*, **2018**, 61, 646-649	5.2	9
50	Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. *Mycoses*, **2018**, 61, 861-867	5.2	9
49	Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. *Oncotarget*, **2018**, 9, 31244-31252	3.3	9
48	Preexposure to Isavuconazole Increases the Virulence of but Not in a Infection Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	9
47	Non-Aspergillus invasive mould infections in patients treated with ibrutinib. *Mycoses*, **2020**, 63, 787-793	5.2	8
46	Rational approach to pulmonary infiltrates in leukemia and transplantation. *Best Practice and Research in Clinical Haematology*, **2013**, 26, 301-6	4.2	8
45	Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7830-2	5.9	8
44	Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 294-7	5.9	8
43	Resistance to Antifungal Drugs. *Infectious Disease Clinics of North America*, **2021**, 35, 279-311	6.5	8

42	Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. *Antimicrobial Agents and Chemotherapy*, **2019**,	5.9	8
41	Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. *MSphere*, **2020**, 5,	5	8
40	Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre- and Post-Hurricane Harvey. *Open Forum Infectious Diseases*, **2019**, 6, ofz138	1	7
39	Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for Eradication of Candida auris Biofilm. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
38	Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. *Clinical Infectious Diseases*, **2020**, 71, 1802-1803	11.6	7
37	Associations of inflammation with symptom burden in patients with acute myeloid leukemia. *Psychoneuroendocrinology*, **2018**, 89, 203-208	5	7
36	Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: An underappreciated association. *Mycoses*, **2021**, 64, 576-582	5.2	7
35	PET-positive lymphadenopathy in CLL-Not always Richter transformation. *American Journal of Hematology*, **2017**, 92, 405-406	7.1	6
34	Investigational antifungal agents for invasive mycoses: a clinical perspective.. *Clinical Infectious Diseases*, **2022**,	11.6	6
33	Aspergillus terreus Species Complex. *Clinical Microbiology Reviews*, **2021**, e0031120	34	6
32	A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. *Journal of Clinical Microbiology*, **2019**, 57,	9.7	5
31	Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. *Clinical Infectious Diseases*, **2010**, 50, 1687-9	11.6	5
30	Serum Levels of Crushed Posaconazole Delayed-Release Tablets. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	4
29	Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds. *MBio*, **2020**, 11,	7.8	4
28	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. *Transplant Infectious Disease*, **2001**, 3, 29-33	2.7	4
27	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. *Blood*, **2020**, 136, 2741-2753	2.2	4
26	Acute acalculous cholecystitis due to Fusarium species and review of the literature on fungal cholecystitis. *Mycoses*, **2019**, 62, 847-853	5.2	3
25	1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. *Open Forum Infectious Diseases*, **2014**, 1, S37-S37	1	3

24	Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	3
23	EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. *Cell Reports*, **2021**, 34, 108896	10.6	3
22	A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies. *Journal of Biomedical Materials Research - Part A*, **2019**, 107, 1867-1874	5.4	2
21	European confederation of medical mycology expert consult-An ECMM excellence center initiative. *Mycoses*, **2020**, 63, 566-572	5.2	2
20	255. Breakthrough Mucormycosis (BT-MCR) on Antifungals Having Mucorales Activity Portrays Worse Prognosis compared with BT-MCR on Mold-Active Antifungals with no Mucorales Activity. *Open Forum Infectious Diseases*, **2019**, 6, S142-S142	1	2
19	Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.. *Frontiers in Immunology*, **2022**, 13, 838344	8.4	2
18	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. *Mycoses*, **2021**,	5.2	2
17	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. *American Journal of Hematology*, **2017**, 92, 119-120	7.1	1
16	Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. *Diagnostic Microbiology and Infectious Disease*, **2019**, 95, 166-170	2.9	1
15	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. *Medical Mycology*, **2020**, 58, 569-578	3.9	1
14	Cat Scratch Disease as a Mimicker of Malignancy.. *Open Forum Infectious Diseases*, **2021**, 8, ofab500	1	1
13	Live imaging and quantitative analysis of growth and morphology during inter-microbial interaction with. *Virulence*, **2020**, 11, 1329-1336	4.7	1
12	Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. *Medical Mycology*, **2018**,	3.9	1
11	Fungal Infections in Cancer Patients **2021**, 792-802		1
10	Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis?. *MBio*, **2022**, e0047322	7.8	1
9	991. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Mortality, Infection Severity, and Fungal Clearance in an Immunosuppressed Murine Model of Invasive Pulmonary Mucormycosis. *Open Forum Infectious Diseases*, **2021**, 8, S586-S586	1	1
8	Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model.. *MSphere*, **2022**, e0081721	5	0
7	Is here to stay? An interview with Dimitrios Kontoyiannis. *Future Microbiology*, **2019**, 14, 1083-1085	2.9	

6	1446Fungemia due to Uncommon Candida species in Patients with Cancer: Increasing Incidence, Frequent Resistance and High Mortality rates. *Open Forum Infectious Diseases*, **2014**, 1, S380-S381	1
5	Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata.. *Microbiology Spectrum*, **2022**, e0183721	8.9
4	Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. *Medical Mycology*, **2021**, 59, 102-105	3.9
3	Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0123021	5.9
2	Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients.. *Frontiers in Cellular and Infection Microbiology*, **2022**, 12, 848580	5.9
1	Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris. *Methods in Molecular Biology*, **2022**, 299-316	1.4